Essai clinique HOVON-177 AML
| Cancers | |
|---|---|
| Organ | Leucémie aigüe |
| Statut | Essai ouvert au recrutement |
| Médecin investigateur | |
| Type d'essai clinique |
Interventionnel avec médicament expérimental
|
| Phase | Phase de l'essai 3 |
| Essai académique | Oui |
| Promoteur | Hovon |
| Identifiant EudraCT | 2024-512733-32-00 |
| Critère(s) d'inclusion | INCLUSION1. Patient with newly diagnosed NPM1-mutated AML OR Patient with newly diagnosed KMT2A-rearranged AML KMT2A partial tandem duplications or deletions are NOT eligible. Of note: in case both NPM1 and IDH1 are mutated and both EVOLVE-1 (HO173) and |
| Mise à jour |